focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: FTSE 100 underperforms as European peers rise

Mon, 12th Feb 2024 12:04

(Alliance News) - London's FTSE 100 underwhelmed on Monday, with some of its largest constituents pulling it lower, while indices in Europe were on the up on favourable comments on interest rate cuts by a European Central Bank official.

The FTSE 100 index fell 11.34 points, 0.2%, at 7,561.24. The FTSE 250 is up 74.94 points, 0.4%, at 19,137.26, and the AIM All-Share added 1.39 points, 0.2%, at 748.80.

The Cboe UK 100 fell 0.1% to 755.81, the Cboe UK 250 climbed 0.7% to 16,572.23, but the Cboe Small Companies fell 0.3% to 14,497.62.

The CAC 40 in Paris and Frankfurt's DAX 40 were both 0.3% higher.

Stocks in New York are set for a muted open. The Dow Jones Industrial Average is called down 0.1%, the S&P 500 flat and the Nasdaq Composite a touch higher.

"Investors are hanging onto every word uttered by anyone affiliated with the major central banks, looking for signs that interest rate cuts are finally on the agenda," AJ Bell analyst Russ Mould commented.

"Expectations that we will soon see this pivot moment have underpinned the pick-up in equity markets since late 2023 and confirmation of the first cut could give another leg-up to stocks and shares. The new trading week saw the spotlight shun on European stocks after ECB Governing Council member Fabio Panetta said the magic moment is 'fast approaching' for the European Central Bank to reduce rates."

The pound was quoted at USD1.2614 early Monday afternoon, down from USD1.2632 late on Friday. The euro stood at USD1.0768, down from USD1.0783. Against the yen, the dollar was trading at JPY149.03, down from JPY149.31.

ING analyst Francesco Pesole commented: "The second-best performing currency after the USD of 2024, the pound, is about to face a couple of key data tests this week. Tomorrow, jobs data for January is released, and Wednesday sees the CPI report and Thursday GDP data.

"Our economics team sees both wage growth and services inflation remaining sticky in the first quarter, meaning that the Bank of England will have no rush to turn to a more dovish communication in the near future. Markets are expecting the BoE to move with a delay (in August) compared to the ECB's and Fed's easing cycles. We agree, but also see 100bp (vs 80bp priced in) of cuts by year-end. Some GBP weakness against the EUR down the road is therefore our base case, but the short-term outlook remains quite constructive for sterling."

It will also be a key week for oil markets. Crude prices were on the decline on Monday, however.

Brent oil was quoted at USD81.16 a barrel early Monday afternoon in London, down from USD82.03 late Friday.

Scope Markets analyst Joshua Mahony commented: "This week sees both Opec and the IEA release their latest monthly reports, with markets keeping a close eye out for any updated supply and demand forecasts. Thus far we have seen the record US output keep a lid on global oil prices, with markets casting aside the historic disruptions to global trade through the Red Sea. However, the recent Saudi decision to reverse the planned 1 million bpd production increase from Aramco highlights the continued efforts to support prices in an oversupplied market. While some will hope that we will soon see a stimulus-led resurgence in Chinese economic activity, we are yet to see any tangible signs of a bounceback that might lift assets such as oil."

Gold fetched USD2,021.68 an ounce, flat from USD2,021.73.

In London, share price falls for pharmaceutical firms put pressure on the FTSE 100. GSK and AstraZeneca, two index heavyweights, fell 0.9% and 1.7%.

AstraZeneca shares came into the week on a three-day losing streak, including a more than 6% slide on the day it released annual results.

"We think this presents a compelling entry point for a best-in-class company," analysts at Barclays said on Monday, however.

NatWest shares fell 2.3%. The lender reports annual results on Friday.

AJ Bell's Mould added: "The UK corporate reporting calendar is fairly quiet until Thursday when Relx and Centrica issue results, followed by NatWest on Friday. In the US, Coca-Cola reports on Tuesday, Cisco on Wednesday and Deere & Co and Applied Materials on Thursday. That's enough to keep investors on their toes."

Tritax Big Box REIT fell 3.2%, while UK Commercial Property REIT added 5.2%, as the duo announced they have agreed to indicative terms for a tie-up.

It will create the UK's fourth-largest real estate investment trust by market capitalisation, at nearly GBP4 billion.

UKCM investors stand to receive 0.444 of a new Tritax Big Box share for every UKCM share they own.

Based on Tritax Big Box's closing share price on Friday, the deal would value each UKCM share at 71.1 pence and the full company's equity at GBP924 million.

The announcement by the two FTSE 250 index constituents represents the latest in a series of mergers of London-listed property companies since the year began. LondonMetric Property and LXi REIT also agreed an all-share merger. Custodian Property Income REIT and abrdn Property Income Trust also struck a deal.

RBC Brewin Dolphin said the Tritax Big Box-UKCM deal is the latest indicator of a "more investible future for UK property", expecting more deals to be announced across 2024 "as more REITs and property companies adapt to higher interest rates and reassess their portfolios amid huge changes in the way property is used."

"At their current scale, the UK's REITs are limited by their size – this has an effect on the capital they can attract, the terms on which they can borrow, and ultimately the deals they can do. Combine them all and you have just one of the main North American property asset managers – they simply can't compete on a global scale," said RBC Brewin Dolphin analyst John Moore.

Galliford Try has landed a place in a GBP3.2 billion affordable homes framework in the UK.

The construction firm said it has won a place on lot 2 of an eight-year Communities & Housing Investment Consortium framework worth GBP2.5 billion, and lot 3, which is worth GBP650 million. Lot 2 includes new build projects and Lot 3 regeneration work.

Galliford shares rose 4.5%.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
16 May 2024 10:27

AstraZeneca trials yield positive results for immunocompromised patients

(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.

Read more
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.